Research and Development, Italfarmaco Group, 20092 Milan, Italy.
Department of Biochemistry, Selvita S.A., 30-394 Kraków, Poland.
Int J Mol Sci. 2024 May 28;25(11):5885. doi: 10.3390/ijms25115885.
Histone deacetylase 6 (HDAC6) is increasingly recognized for its potential in targeted disease therapy. This study delves into the mechanistic and structural nuances of HDAC6 inhibition by difluoromethyl-1,3,4-oxadiazole (DFMO) derivatives, a class of non-hydroxamic inhibitors with remarkable selectivity and potency. Employing a combination of nuclear magnetic resonance (NMR) spectroscopy and liquid chromatography-mass spectrometry (LC-MS) kinetic experiments, comprehensive enzymatic characterizations, and X-ray crystallography, we dissect the intricate details of the DFMO-HDAC6 interaction dynamics. More specifically, we find that the chemical structure of a DMFO and the binding mode of its difluoroacetylhydrazide derivative are crucial in determining the predominant hydrolysis mechanism. Our findings provide additional insights into two different mechanisms of DFMO hydrolysis, thus contributing to a better understanding of the HDAC6 inhibition by oxadiazoles in disease modulation and therapeutic intervention.
组蛋白去乙酰化酶 6(HDAC6)因其在靶向疾病治疗中的潜力而受到越来越多的关注。本研究深入探讨了二氟甲基-1,3,4-噁二唑(DFMO)衍生物抑制 HDAC6 的机制和结构细节,DFMO 衍生物是一类具有显著选择性和效力的非羟肟酸抑制剂。本研究采用核磁共振(NMR)光谱和液相色谱-质谱(LC-MS)动力学实验、全面的酶学特性分析以及 X 射线晶体学相结合的方法,剖析了 DFMO-HDAC6 相互作用动力学的复杂细节。具体而言,我们发现 DMFO 的化学结构及其二氟乙酰基酰肼衍生物的结合模式对于确定主要水解机制至关重要。我们的研究结果提供了关于 DFMO 水解的两种不同机制的更多见解,有助于更好地理解噁二唑类化合物在疾病调节和治疗干预中对 HDAC6 的抑制作用。